Results 41 to 50 of about 302,269 (383)
Drugs of Today, 2007 Pioglitazone and metformin have both proven safe and efficacious in the treatment of type 2 diabetes. Their combination into a single tablet seems logical. This article reviews the data that are available for this combination. Because the tablets are not currently widely available, the review examines some aspects of the effects of both agents ...
Hill, N, Matthews, DR
openaire +4 more sources
Drugs in R & D, 2005 Metformin extended release [Glumetza, metformin hydrochloride, metformin gastric retention, metformin GR] is a proprietary once-a-day formulation of metformin hydrochloride under development with Depomed for the treatment of diabetes mellitus. In May 2002, Depomed licensed manufacturing and marketing rights for its proprietary formulation of metformin ...
openaire +4 more sources
Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2 [PDF]
, 2014 The antiglycemic drug metformin, widely prescribed as first-line treatment of type II diabetes mellitus, has lifespan-extending properties. Precisely how this is achieved remains unclear.
Billen, Johan +8 more
core +1 more source
Metformin treatment for diabetes mellitus correlates with progression and survival in colorectal carcinoma [PDF]
, 2020 BACKGROUND: Diabetes mellitus is unfavorably associated with cancer risk. The purpose of this multi-disciplinary project was to evaluate a possible association of diabetes mellitus and other comorbidities and their treatment with progression of ...
Brown, Robert E. +10 more
core +1 more source
Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner
OncoImmunology, 2021 Metformin, a drug prescribed to treat type 2 diabetes, has been reported to possess antitumor activity via immunity activation. However, the influence of metformin on natural killer (NK) cells is not fully understood.
Wenjiao Xia +7 more
doaj +1 more source
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial [PDF]
, 2009 <br>Background: Metformin reduces cardiovascular risk in patients with type 2 diabetes seemingly independent of lowering blood glucose concentration. We assessed the cardiovascular effects of metformin in individuals without type 2 diabetes.</br&
Eddy +33 more
core +5 more sources
Metformin: a modulator of bevacizumab activity in cancer? A case report. [PDF]
, 2015 Recurrent type I endometrial cancer ((EC)) has poor prognosis and demands novel therapeutic approaches. Bevacizumab, a VEGF-A neutralizing monoclonal antibody, has shown clinical activity in this setting. To our knowledge, however, although some diabetic
Aliberti, C +7 more
core +1 more source
Diabetes Care, 2021 OBJECTIVE To determine the longer-term effects of metformin treatment and behavioral weight loss on gut microbiota and short-chain fatty acids (SCFAs). RESEARCH DESIGN AND METHODS We conducted a 3-parallel-arm, randomized trial.
N. Mueller +7 more
semanticscholar +1 more source
Polish Gynaecology, 2014 Metformin is an oral insulin-sensitizing anti-diabetic drug. Polycystic ovary syndrome (PCOS) and gestational diabetes (GDM) are both associated with insulin resistance and hyperinsulinemia. Metformin can bring potential benefits in pregnant women due to its favorable metabolic effect.
Małgorzata Bińkowska +2 more
openaire +3 more sources
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth. [PDF]
PLoS ONE, 2015 Recently, the pleiotropic benefits of incretin-based therapy have been reported. We have previously reported that Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist, attenuates prostate cancer growth.
Yoko Tsutsumi +9 more
doaj +1 more source